X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
1. Apo-ferrous Gluconate
2. Dextriferron
3. Eisen-sandoz
4. Feg Iron
5. Fergon
6. Ferroglucon
7. Ferrogluconaat Fna
8. Ferrous Gluconate
9. Ferrum Verla
10. Loesferron
11. Losferron
12. Rulofer G
13. Simron
14. Vitaferro Brause
1. Ferrous Gluconate
2. Ferrousgluconate
3. Iron Gluconate
4. Ferrous Gluconate Anhydrous
5. 299-29-6
6. Iron(ii) Gluconate, Anhydrous
7. 781e2axh0k
8. Iron(2+) Gluconate (1:2)
9. 18829-42-0
10. D-gluconic Acid, Iron(2+) Salt (2:1)
11. Iron(2+);(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate
12. Ferrous Gluconate Dihydrate
13. Ferroglyconicum
14. Biofergate
15. Ferronicum
16. Glucoferron
17. Feravol
18. Ferlucon
19. Ferrose
20. Flourish
21. Glucomax
22. Gluferate
23. Nionate
24. Entron
25. Fenton
26. Ferox
27. Irox
28. Ferro-agepha
29. Ferrum Polon
30. Gluco-ferrum
31. Ray-gluciron
32. Iromon (gador)
33. Fergon Preparations
34. Iron-ii Gluconate
35. Irox (gador)
36. Ferrin 55
37. Gluconic Acid Iron Salt
38. 6047-12-7
39. Ferrous Gluconate [usan]
40. Unii-781e2axh0k
41. Hsdb 461
42. Iron Digluconate
43. Iron, Bis(d-gluconato-o1,o2)-
44. Einecs 206-076-3
45. 699014-53-4
46. Gluconic Acid, Iron(2+) Salt (2:1), D-
47. Ec 206-076-3
48. Schembl35424
49. Ferrous Gluconate [mi]
50. Ferrous Gluconate [hsdb]
51. Akos015901488
52. Db14488
53. Gluconic Acid, Iron(2+) Salt (2:1)
54. Iron, Bis(d-gluconato-kappao1,kappao2)-
55. Q421291
| Molecular Weight | 446.14 g/mol |
|---|---|
| Molecular Formula | C12H22FeO14 |
| Hydrogen Bond Donor Count | 10 |
| Hydrogen Bond Acceptor Count | 14 |
| Rotatable Bond Count | 8 |
| Exact Mass | 446.035891 g/mol |
| Monoisotopic Mass | 446.035891 g/mol |
| Topological Polar Surface Area | 283 Ų |
| Heavy Atom Count | 27 |
| Formal Charge | 0 |
| Complexity | 165 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 8 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 3 |
HEMATINIC
O'Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. 13th Edition, Whitehouse Station, NJ: Merck and Co., Inc., 2001., p. 716
...Iron absorption tests were performed on 55 patients 3.2+/-2.0 years after isolated gastric bypass to identify those at higher risk for the late development of anemia. Twenty-nine of this group agreed to a therapeutic trial of iron /gluconate/ alone or with vitamin C over a 2-month period. All 55 patients were followed up for 27.1+/-1.0 months following the study. The iron absorption test identified patients with low iron stores, as indicated by low serum ferritin, and those with sufficient absorption surface to benefit from oral iron. The addition of vitamin C appears to enhance the therapeutic effect of iron by correcting ferritin deficits (P < 0.01) and anemia (P < 0.05). Differences in intestine length bypassed by the operation (10 vs. 100 cm) did not affect late ferritin and hemoglobin values.
PMID:10065575 Rhode BM et al; Obes Surg 9 (1): 17-21 (1999)
...A study was... conducted on 40 women aged 20-35, with iron-deficiency anemia during or immediately after pregnancy all of whom presented Hb <10 gr/dL, Ht <33% and serum iron <60 ug/dL. All women with pregnancy-related pathological conditions, pre-existing on concomitant disease (Type I diabetes, heart diseases etc.) were excluded from the study. The women whose blood chemical parameters were largely homogeneous at the start of the study were divided into four treatment groups of 10 patients each and were treated as follows: Group A with oral liquid ferrous gluconate (75 mg per diem in 2 vials a day); Group B with solid ferrous gluconate (80 mg per diem in a single effervescent tablet); Group C with solid ferrous sulfate (105 mg per diem in a single tablet); and Group D with ferric protein succinylate (80 mg per diem in 2 vials a day). All were given iron treatment for 30 days. Treatment efficacy was analysed by comparing basal and final parameters using the T-test for paired dependent samples. The tolerance of the 4 treatment protocols was assessed by the analysis of any side effects such as nausea, vomiting, epigastric pain, diarrhea, constipation or other disorders reported by patients during treatment. Analysis of the therapeutic efficacy parameters (red blood cells, hemoglobin, hematocrit and serum iron) showed significant improvements but no statistically significant differences between the groups. However, the Group A patients treated with oral doses of liquid ferrous gluconate received a significantly lower cumulative dose of iron elements than the other groups: in detail 150 mg (p<0.05) less than Groups B and D; 900 mg (<0.001) less than Group C. By the end of treatment the Group A patients revealed significant increases versus basal values in red blood cells (p<0.001) 1,051,000 per cu mm or 33%, in Hb (p<0.001) 2.83 gr/dL or 32%, in Ht (p<0.001) 8.32% or 32%, in serum iron (p<0.05) 19.5 ug/dL or 61%. The same group also showed an increase in ferritin amounting to 7.8 ug/dL or 24% of the basal value. As to safety, only Group A patients reported no side effects and produced no drop-outs. Gastrointestinal and other aspecific side effects caused 1 drop-out each in Groups B and C and 2 drop-outs in Group D.
PMID:9005381 Casparis D et al; Minerva Ginecol 48 (11): 511-518 (1996)
...A study was therefore conducted on 40 women aged 20-35, with iron-deficiency anemia during or immediately after pregnancy all of whom presented Hb <10 gr/dL, Ht <33% and serum iron <60 ug/dL. ...As to safety, only Group A patients reported no side effects and produced no drop-outs. Gastrointestinal and other aspecific side effects caused 1 drop-out each in Groups B and C and 2 drop-outs in Group D.
PMID:9005381 Casparis D et al; Minerva Ginecol 48 (11): 511-518 (1996)
The effect of long-term oral iron supplementation on morbidity due to diarrhea, dysentery and respiratory infections in 349 children, aged 2-48 months, living in a poor community of Bangladesh, was evaluated in this double-blind study. The treatment group received 125 mg of ferrous gluconate (15 mg elemental iron) plus multivitamins and the controls received only multivitamins, daily for 15 months. House-to-house visits were made on alternate days by trained community health workers for recording symptoms and duration of illnesses and for monitoring medicine intake. Seventy-six percent of the children continued the syrup for over 1 yr. No untoward effects were noticed in either treatment group. The attack rates for diarrhea, dysentery and acute respiratory tract infections (ARI) were 3, 3 and 5 episodes per child per year, respectively. Each episode of diarrhea lasted a mean of 3 days, and those of dysentery and ARI, 5 days. The two treatment groups did not differ in the number of episodes, mean duration of each episode, or total days of illnesses due to diarrhea, dysentery and ARI. However, a 49% greater number of episodes of dysentery was observed with iron supplementation in a subset of the study children who were less than 12 months old (P=0.03).
PMID:9237937 Mitra AK et al; J Nutr 127 (8): 1451-5 (1997)
Used in preventing and treating iron-deficiency anemia.
The major activity of supplemental iron is in the prevention and treatment of iron deficiency anemia. Iron has putative immune-enhancing, anticarcinogenic and cognition-enhancing activities.
Hematinics
Agents which improve the quality of the blood, increasing the hemoglobin level and the number of erythrocytes. They are used in the treatment of anemias. (See all compounds classified as Hematinics.)
B - Blood and blood forming organs
B03 - Antianemic preparations
B03A - Iron preparations
B03AA - Iron bivalent, oral preparations
B03AA03 - Ferrous gluconate
B - Blood and blood forming organs
B03 - Antianemic preparations
B03A - Iron preparations
B03AD - Iron in combination with folic acid
B03AD05 - Ferrous gluconate
Absorption
The efficiency of absorption depends on the salt form, the amount administered, the dosing regimen and the size of iron stores. Subjects with normal iron stores absorb 10% to 35% of an iron dose. Those who are iron deficient may absorb up to 95% of an iron dose.
The iron bioavailability and acute oral toxicity in rats of a ferrous gluconate compound stabilized with glycine (SFG), designed for food fortification, was studied in this work by means of the prophylactic method and the Wilcoxon method, respectively. For the former studies, SFG was homogeneously added to a basal diet of low iron content, reaching a final iron concentration of 20.1 +/- 2.4 mg Fe/kg diet. A reference standard diet using ferrous sulfate as an iron-fortifying source (19.0 +/- 2.1 mg Fe/kg diet) and a control diet without iron additions (9.3 +/- 1.4 mg Fe/kg diet) were prepared in the laboratory in a similar way. These diets were administered to three different groups of weaning rats during 23 d as the only type of solid nourishment. The iron bioavailability of SFG was calculated as the relationship between the mass of iron incorporated into hemoglobin during the treatment and the total iron intake per animal. This parameter resulted in 36.6 +/- 6.2% for SFG, whereas a value of 35.4 +/- 8.0% was obtained for ferrous sulfate.
PMID:12907829 Lysionek AE et al; Biol Trace Elem Res 94 (1): 73-8 (2003)
Gastrointestinal absorption of iron is adequate and essentially equal from...ferrous...sulfate, fumarate, gluconate, succinate, glutamate, and lactate.
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 1315
Iron is necessary for the production of hemoglobin. Iron-deficiency can lead to decreased production of hemoglobin and a microcytic, hypochromic anemia.
Market Place
